Bevacizumab

Bevacizumab, a monoclonal antibody, is developed to bind with vascular endothelial growth factor (VEGF), which is a protein stimulating new blood vessel formation. It also acts by blocking VEGF to limit the blood supply that the tumors require in order to increase and spread. This renders it a significant oncological targeted therapy.

Category: Oncology Exporter Company from India

Description
Reviews (0)

Description

Uses

Metastatic colorectal cancer (metastatic)
Lung cancer that is not small-cell cancer
Kidney cancer
Ovarian and cervical cancers
Glioblastoma (Brain tumor)
Off-label: eye disorders such as age-related macular degeneration

Benefits:

Restrict tumor growth by minimizing the formation of blood vessels.
Helps in the chemotherapy process with combined usage.
Assists in enhancing progression-free and overall survival in various cancers.
It can be applied to various tumors.

Administration

Administered as an IV infusion by a practitioner.
The frequency and dose vary according to cancer and patient condition.
Frequently used with chemotherapy or other specific therapies.

Side Effects

Ordinary: hypertension, epistaxis, fatigue, mucus, headache
Severe: Slow recovery of wounds, blood clots, bleeding, gastric holes, blood in the urine, kidney issues (protein in the urine)

Conclusion

Bevacizumab is an effective targeted cancer therapy that has meaningful advantages in the management of cancer growth and survival when administered adequately. It offers inspiration to patients with terminal cancers, but this needs to be closely monitored; it has certain risks and side effects.